Grand Pharma says US DOORwaY90 trial of SIR-Spheres Y-90 in HCC hits endpoint

  • Grand Pharmaceutical reported its US DOORwaY90 study of SIR-Spheres Y-90 resin microsphere injection in unresectable liver cancer reached its clinical endpoint.
  • Study outcomes showed strong tumor response with durable benefit while preserving liver function, supporting Y-90 radioembolization as a definitive treatment option for unresectable disease.
  • FDA had already cleared SIR-Spheres for unresectable hepatocellular carcinoma based on interim DOORwaY90 data, making it first selective internal radiotherapy product with dual US indications in liver cancer and colorectal cancer liver metastases.
  • Relevant clinical data will be presented in the future, with management positioning results as support for expanding indications in China.
  • Grand Pharma flagged nuclear medicine segment revenue of about HK$950 million in 2025, up 61%, with SIR-Spheres cited as key growth driver.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grand Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260413-12104117), on April 13, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.